217 related articles for article (PubMed ID: 576512)
1. A comparative ex vivo study of plasminogen activators and proteases for fibrinolytic activity and side effects in rabbits.
Janik BA; Papaioannou SE
Thromb Haemost; 1977 Feb; 37(1):154-61. PubMed ID: 576512
[TBL] [Abstract][Full Text] [Related]
2. [Changes in the components of the animal fibrinolytic system induced by the action of physiological activators and enzymes of fungal origin].
Andreenko GV; Serebriakova TN; Shimonaeva EE; Liutova LV; Karabasova MA
Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (3):51-4. PubMed ID: 6342687
[TBL] [Abstract][Full Text] [Related]
3. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolytic agents.
Schmitz-Huebner U; van de Loo J
Clin Haematol; 1981 Jun; 10(2):481-96. PubMed ID: 7032785
[No Abstract] [Full Text] [Related]
5. Activation of the fibrinolytic system.
Robison AK; Collen D
Cardiol Clin; 1987 Feb; 5(1):13-9. PubMed ID: 3103919
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
7. [Effect of the enzyme preparation longolytin on fibrinolysis in animals].
Serebriakova TN; Andreenko GV; Tsymanovich SG; Maksimova RA; Sharkova TS
Nauchnye Doki Vyss Shkoly Biol Nauki; 1985; (2):66-71. PubMed ID: 3157406
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of fibrinolytic enzymes in vivo.
Ambrus JL; Weber FJ; Ambrus CM
J Med; 1979; 10(1-2):99-119. PubMed ID: 158624
[TBL] [Abstract][Full Text] [Related]
9. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria.
Hanbücken FW; Schneider J; Günzler WA; Friderichs E; Giertz H; Flohé L
Arzneimittelforschung; 1987 Aug; 37(8):993-7. PubMed ID: 3118890
[TBL] [Abstract][Full Text] [Related]
10. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
[No Abstract] [Full Text] [Related]
11. Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro.
Ries M; Zenker M; Klinge J; Keuper H; Harms D
J Pediatr Hematol Oncol; 1995 Aug; 17(3):260-4. PubMed ID: 7620925
[TBL] [Abstract][Full Text] [Related]
12. [Position and developmental trends in fibrinolytic therapy].
Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):6-17. PubMed ID: 2427416
[TBL] [Abstract][Full Text] [Related]
13. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
Bode C; Eberle T; Runge M; Haber E; Kübler W
Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
[No Abstract] [Full Text] [Related]
14. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
van Giezen JJ; Boon GI; Jansen JW; Bouma BN
Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
[TBL] [Abstract][Full Text] [Related]
15. [Blood coagulating properties of immobilized proteases].
Zubairov DM; Zinkevich OD
Vopr Med Khim; 1976; 22(2):187-91. PubMed ID: 140525
[TBL] [Abstract][Full Text] [Related]
16. [Thrombolytics and their use].
Alessi MC; Juhan-Vague I
Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
[TBL] [Abstract][Full Text] [Related]
17. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
Gurewich V; Pannell R
Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
[No Abstract] [Full Text] [Related]
18. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
Veremeenko KN; Kizim AI
Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
[TBL] [Abstract][Full Text] [Related]
19. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]